What does 96.4% purity on a C8 column actually tell me about a tirzepatide vial?

What I have: 96.4% · a C8 column · tirzepatide.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

What is the correct interpretation, and what is the common misreading?

It tells you 96.4 per cent of the integrated area came off a C8 column where tirzepatide comes off, and the remaining 3.6 per cent did not. That is an area statement at one wavelength, not a mass statement about the vial: 3.6 per cent of area is only 3.6 per cent of mass if every impurity absorbs exactly as strongly as the parent, which none of them do. It also says nothing about how many milligrams are in the glass — water, counter-ion and a short fill are all invisible to it. What a C8 column does add is a constraint on what could be hiding: a column that retains by hydrophobicity separates deletion sequences well and separates isomers of identical hydrophobicity not at all.

Put another way, high-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

The most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

It helps to be literal here: temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

The limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

Ask for the chromatogram and the system suitability data, not just the number.

edited 11 Jul 2026 by a_lindgren — reworded for clarity after a comment

To be exact about it, coupling the chromatography to mass spectrometry adds identity information but trades chromatographic quality for ionisation efficiency.

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 22 May 2026 by gradient_slope — added the method parameters